Spironolactone as a therapeutic alternative for the bullous variant of central serous chorioretinopathy

Conclusion: We suggest the use of mineralocorticoid receptor antagonists, such as spironolactone, as a therapeutic alternative to more aggressive available treatments for the bullous variant of central serous chorioretinopathy.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research